From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rapacuronium bromide
Rapacuronium bromide.svg
Systematic (IUPAC) name
(2β,3α,5α,16β,17β)-3-(acetyloxy)-16-(1-allylpiperidinium-1-yl)-2-piperidin-1-yl-17-(propionyloxy)androstane bromide
Clinical data
  • US: C
  • Withdrawn (U.S)
Pharmacokinetic data
Bioavailability Not applicable
Protein binding Variable
Metabolism Hydrolyzed to active metabolites
CYP system not involved
Half-life 141 minutes (mean)
Excretion Renal and fecal
156137-99-4 N
PubChem CID 5311398
DrugBank DB04834 YesY
ChemSpider 4470889 YesY
Synonyms [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate
Chemical data
Formula C37H61N2O4+
597.891 g/mol
 N (what is this?)  (verify)

Rapacuronium (Raplon) is a rapidly acting, non-depolarizing neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.[1]


  1. ^ Shapse, Deborah (March 27, 2001). Voluntary Market Withdrawal PDF (10.8 KiB). Organon International. Retrieved on 2007-04-02.